Also Known As
CA 125 Tumor Marker
Formal Name
Cancer Antigen 125
This article was last reviewed on
This article waslast modified on August 13, 2020.
At a Glance
Why Get Tested?

To monitor treatment for ovarian cancer or to detect recurrence of disease; sometimes to evaluate a lump located in the pelvic area (pelvic mass); not recommended for screening asymptomatic women but sometimes ordered to help detect early ovarian cancer in those identified as being at high risk

When To Get Tested?

Before starting therapy for ovarian cancer and at intervals during and after treatment; sometimes when you have a pelvic mass or are at a high risk for developing ovarian cancer

Sample Required?

A blood sample drawn from a vein in your arm

Test Preparation Needed?

None

You may be able to find your test results on your laboratory's website or patient portal. However, you are currently at Lab Tests Online. You may have been directed here by your lab's website in order to provide you with background information about the test(s) you had performed. You will need to return to your lab's website or portal, or contact your healthcare practitioner in order to obtain your test results.

Lab Tests Online is an award-winning patient education website offering information on laboratory tests. The content on the site, which has been reviewed by laboratory scientists and other medical professionals, provides general explanations of what results might mean for each test listed on the site, such as what a high or low value might suggest to your healthcare practitioner about your health or medical condition.

The reference ranges for your tests can be found on your laboratory report. They are typically found to the right of your results.

If you do not have your lab report, consult your healthcare provider or the laboratory that performed the test(s) to obtain the reference range.

Laboratory test results are not meaningful by themselves. Their meaning comes from comparison to reference ranges. Reference ranges are the values expected for a healthy person. They are sometimes called "normal" values. By comparing your test results with reference values, you and your healthcare provider can see if any of your test results fall outside the range of expected values. Values that are outside expected ranges can provide clues to help identify possible conditions or diseases.

While accuracy of laboratory testing has significantly evolved over the past few decades, some lab-to-lab variability can occur due to differences in testing equipment, chemical reagents, and techniques. This is a reason why so few reference ranges are provided on this site. It is important to know that you must use the range supplied by the laboratory that performed your test to evaluate whether your results are "within normal limits."

For more information, please read the article Reference Ranges and What They Mean.

What is being tested?

Cancer Antigen 125 (CA-125) is a protein that is present on the surface of most, but not all, ovarian cancer cells. This makes the test useful as a tumor marker in specific circumstances. The CA-125 test measures the amount of CA-125 protein in your blood.

Significantly elevated concentrations of CA-125 may be present in the blood of a woman who has ovarian cancer. Thus, the test may be used to monitor the effectiveness of treatment and/or for recurrence of the cancer. However, not all women with ovarian cancer will have elevated CA-125 so the test may not be useful in all cases.

Ovarian cancer is the fifth most common cause of cancer death in women. According to the American Cancer Society (ACS), the lifetime risk of a woman developing ovarian cancer is about 1 in 78 and the lifetime risk of death is 1 in 108. ACS estimates that in 2019 about 22,530 women will be diagnosed with ovarian cancer in the U.S. and about 13,980 women will die of it.

Currently, less than 20% of ovarian cancers are found in the early stages before they have spread outside the ovary. The primary reason they go undetected is that the symptoms of ovarian cancer are fairly non-specific.

The need for a reliable method for early detection of ovarian cancer among asymptomatic women continues to drive ongoing research. In the meantime, regular physicals, pelvic exams, and an awareness of your family history and symptoms are important.

CA-125 is not recommended as a screening test for asymptomatic women because it is non-specific. Small quantities of CA-125 are produced by normal tissues throughout your body and by some other cancers. Levels in your blood may be moderately elevated with a variety of non-cancerous conditions, including menstruation, pregnancy, and pelvic inflammatory disease.

Accordion Title
Common Questions
  • How is the test used?

    CA-125 is a tumor marker primarily used to monitor therapy during treatment for ovarian cancer. CA-125 is also used to detect whether your cancer has come back after treatment is completed. A series of CA-125 tests that shows rising or falling levels is often more useful than a single result.

    CA-125 is sometimes used along with transvaginal ultrasound to test and monitor women who have a high risk for ovarian cancer but who do not yet have the disease. The most significant risk factor for ovarian cancer is an inherited genetic variant in one of two genes: breast cancer gene1 (BRCA1) or breast cancer gene 2 (BRCA2) - see BRCA Gene Mutation Testing. Women with an inherited condition called Lynch syndrome may also have a higher risk of ovarian cancer (a lifetime risk of about 10%). Other risk factors are family history, increasing age, reproductive history and infertility, use of hormone replacement therapy, and obesity.

    Sometimes a CA-125 test may be ordered along with a transvaginal ultrasound to help investigate a lump in woman's lower abdominal area (pelvic mass.)

    The test is not used, however, to screen women for ovarian cancer because it is non-specific. The U.S. Preventive Services Task Force recommends against screening women for ovarian cancer. This recommendation applies to asymptomatic women but not to women at high risk for developing ovarian cancer, such as those with a genetic mutation.

    Currently, there is no one reliable method for early detection of ovarian cancer among asymptomatic women. Less than 20% of ovarian cancers are found in the early stages before they have spread outside the ovary. One reason they go undetected is that the symptoms of ovarian cancer are fairly non-specific. In the meantime, regular physicals, pelvic exams, and an awareness of your family history and other risk factors are important. (For more about ovarian cancer, see the "What is being tested?" section or the article on Ovarian Cancer.)

  • When is it ordered?

    The CA-125 test may be ordered before you start ovarian cancer treatment as a baseline to compare against future measurements. During therapy, a healthcare practitioner may order CA-125 testing at intervals to monitor response to therapy. CA-125 may also be measured periodically after therapy is completed.

    In some cases, a healthcare practitioner may order a CA-125 test when you have a pelvic mass in order to help determine the cause.

    Some healthcare providers may order a CA-125 test and a transvaginal ultrasound at regular intervals when you are at high risk of developing ovarian cancer.

  • What does the test result mean?
    • If your CA-125 levels are initially high and then fall during therapy, this generally indicates that the cancer is responding to treatment.
    • If the CA-125 levels rise or stay the same, then your cancer may not be responding to therapy.
    • An initial fall of CA-125 levels after treatment is completed with a subsequent rise in CA-125 levels may indicate that your cancer has come back.

    If you have been diagnosed with ovarian cancer and your baseline CA-125 level is normal, then the test is not likely to be useful to monitor your ovarian cancer. In this case, the ovarian cancer may not be producing CA-125 and is not a good marker of disease progression.

    If you have a pelvic mass and are at a high risk for developing ovarian cancer, a significantly elevated CA-125 is a concern but does not necessarily indicate ovarian cancer. This finding would prompt further laboratory testing and clinical evaluation.

  • Why isn’t CA-125 used to screen for ovarian cancer?

    Because CA-125 can be high in many normal or benign conditions, such as pregnancy, menstruation, endometriosis, and pelvic inflammatory disease, it is not useful or recommended as a screening test for the general population.

  • Are there other tumor markers used in ovarian cancer?

    A new tumor marker, human epididymis protein 4 (HE4), may be ordered along with CA-125 to monitor epithelial cell tumors, the most common type of ovarian cancers. These cancers develop from the cells that cover the outside of the ovaries. The use and full clinical utility of this test has yet to be determined.

  • Is CA-125 always increased in ovarian cancer?

    No, not all ovarian cancers are associated with increased levels of CA-125. Elevated levels have been found in about 80% of women with ovarian cancer.

  • Does ovarian cancer run in families?

    Family history is a risk factor for ovarian cancer. If you have close family members who have had ovarian cancer, you are at higher risk than someone who has no family history of the disease. Make sure your healthcare providers know about your family medical history. Women who have inherited a mutation in one of the BRCA genes are at high risk of ovarian cancer. For more details, see the article on BRCA Gene Mutation Testing.

  • What are some other risk factors for ovarian cancer?

    In addition to family history, other risk factors include increasing age, obesity, and use of hormone replacement therapy. See the American Cancer Society website for more on this.

View Sources

Sources Used in Current Review

King, G. and Leighton, J. (2019 July 10, Updated). CA 125. Medscape Laboratory Medicine. Available online at https://emedicine.medscape.com/article/2087557-overview. Accessed on 11/9/19.

(2019 April, Updated). Ovarian Cancer FAQ. ACOG. Available online at https://www.acog.org/Patients/FAQs/Ovarian-Cancer. Accessed on 11/9/19.

(2018 November 13, Updated). CA-125 Blood Test (Ovarian Cancer). NIH MedlinePlus. Available online at https://medlineplus.gov/lab-tests/ca-125-blood-test-ovarian-cancer/. Accessed on 11/9/19.

(2018 February 13). Screening for Ovarian Cancer US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(6):588-594. Available online at https://jamanetwork.com/journals/jama/fullarticle/2672638. Accessed on 11/9/19.

Green, A. et. al. (2019 October 1, Updated). Ovarian Cancer. Medscape Oncology. Available online at https://emedicine.medscape.com/article/255771-overview. Accessed on 11/9/19.

(© 1995–2019). Cancer Antigen 125 (CA 125), Serum. Mayo Clinic Laboratories. Available online at https://www.mayocliniclabs.com/test-catalog/Overview/9289. Accessed on 11/9/19.

(2019 March 22, Updated). Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening (PDQ) – Health Professional Version. National Cancer Institute. Available online at https://www.cancer.gov/types/ovarian/hp/ovarian-screening-pdq. Accessed on 11/9/19.

Bayrak-Toydemir, P. et al. Medical Experts (2019 October, Updated). Ovarian Cancer. ARUP Consult. Available online at https://arupconsult.com/content/ovarian-cancer?_ga=2.226283929.2056076676.1573304696-1793245273.1560683717. Accessed on 11/9/19.

(2018 April 11, Updated). Can Ovarian Cancer Be Found Early? American Cancer Society. Available online at http://www.cancer.org/cancer/ovarian-cancer.html. Accessed on 11/9/19.

Sources Used in Previous Reviews

Thomas, Clayton L., Editor (1997). Taber's Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].

Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby's Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.

Pagana, K. D. & Pagana, T. J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 219-220.

Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 210-211.

Mason, J. (Updated 2008 June 10). CA-125. MedlinePlus Medical Encyclopedia. [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/007217.htm. Accessed March 2009.

(2007 March). Ovarian Cancer Resource Guide for women with recurrent disease. NOCC, Inc. [On-line information]. PDF available for download at http://www.ovarian.org/Images/ResourceGuideRecurrentOvarianCancer.pdf. Accessed March 2009.

(2008 August 26). Ovarian Cancer: Why Screening Isn't Routine. American Cancer Society. [On-line information]. Available online at http://www.cancer.org/docroot/SPC/content/SPC_1_ovarian_Q_A_Saslow.asp. Accessed March 2009.

(Modified 2008 April 3). Ovarian Cancer Screening (PDQ®), Health Professional Version. NCI, U.S. National Institutes of Health. [On-line information]. Available online at http://www.cancer.gov/cancertopics/pdq/screening/ovarian/healthprofessional. Accessed March 2009.

(2008 July). Understanding CA 125 Levels: A Guide for Ovarian Cancer Patients. Gynecologic Cancer Foundation. [On-line information]. PDF available for download at http://www.thegcf.org/wcnlib/downloads/CA125levels_July2008.pdf. Accessed March 2009.

(Updated 2012 August 1). Fazal Hussain, F. and Homoud, H. Gynecologic Tumor Markers Tumor Marker Overview. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/269839-overview. Accessed October 2012.

Zieve, D. and Chen Y. (Updated 2011 December 15). CA-125. MedlinePlus Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/007217.htm. Accessed October 2012.

(Revised 2012 October 5). Can ovarian cancer be found early? American Cancer Society [On-line information]. Available online at http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-detection. Accessed October 2012.

Grenache, D. et. al. (Updated 2012 May). Ovarian Cancer. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/OvarianCancer.html?client_ID=LTD. Accessed October 2012.

Schmidt, C. (2011 December 05). CA-125: A Biomarker Put to the Test. Medscape Today News from J Natl Cancer Inst. V 103(17):1290-1281 [On-line information]. Available online at http://www.medscape.com/viewarticle/750770. Accessed October 2012.

Rustin, G. et. al. (2012 March 08). CA-125: To Monitor or Not to Monitor? For Ovarian Cancer Patients in Remission. Medscape Today News [On-line information]. Available online at http://www.medscape.com/viewarticle/759809. Accessed October 2012.

(2012 September). Screening for Ovarian Cancer, U.S. Preventive Services Task Force Reaffirmation Recommendation Statement. USPSTF [On-line information]. Available online at http://www.uspreventiveservicestaskforce.org/uspstf12/ovarian/ovarcancerrs.htm. Accessed November 2012.

Pagana, K. D. & Pagana, T. J. (© 2011). Mosby's Diagnostic and Laboratory Test Reference 10th Edition: Mosby, Inc., Saint Louis, MO. Pp 210-211.

Clarke, W., Editor (© 2011). Contemporary Practice in Clinical Chemistry 2nd Edition: AACC Press, Washington, DC. Pp 499-500.

2016 review by Carolyn Sue Ziegler, MBA, MLS(CM).

Pagana, Kathleen D, Pagana, Timothy J, and Pagana, Theresa N. (©2015) Mosby’s Diagnostic & Laboratory Test Reference 12th Edition: Mosby, Inc. Saint Louis, MO. Pp.199-200.

(Updated Oct. 30, 2015) Gentry George T King, M.D. CA 125: Reference Range, Interpretation, Collection and Panels. Available online at http://emedicine.medscape.com/article/2087557-overview. Accessed 23/2016.

Ovarian Cancer National Alliance. Risk Factors. Available online at http://www.ovariancancer.org/about/risk-factors. Accessed 2/8/2016.

Ovarian Cancer National Alliance. Symptoms and Detection of Ovarian Cancer. Available online at http://www.ovariancancer.org/about/symptoms-of-ovarian-cancer-detection. Accessed 2/8/2016.

(Updated 13 January 2016) CA-125 blood test. MedlinePlus Medical Encyclopedia. Available online at https://www.nlm.nih.gov/medlineplus/ency/article/007217.htm. Accessed 2/3/2016.

(©2016) Mayo Clinic Mayo Medical Laboratories. Human Epididymis Protein 4, Serum. Available online at http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/62137. Accessed 2/10/2016.

Ovarian Cancer Testing: HE4 Ovarian Cancer Monitoring. Quest Diagnostics. Available online at http://www.questdiagnostics.com/home/patients/tests-a-z/ovarian-cancer/he4-monitoring.html. Accessed Feb 2016.

(©2014) Laboratory Corporation of America. A Technical Review, Human Epididymis Protein 4 (HE4), Monitoring Patients With Epithelial Ovarian Carcinoma.

(Jan 14, 2015) Fazal Hussain. Gynecologic Tumor Markers, Cancer Antigen 125. Medscape Review. Available online at http://emedicine.medscape.com/article/269839-overview#a2. Accessed 2/8/2016.

(Aug 5, 2014) American Cancer Society. Ovarian Cancer: Detailed Guide. Available online at http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-what-is-ovarian-cancer. Accessed 2/8/2016.

Ask a Laboratory Scientist

This form enables patients to ask specific questions about lab tests. Your questions will be answered by a laboratory scientist as part of a voluntary service provided by one of our partners, American Society for Clinical Laboratory Science. Please allow 2-3 business days for an email response from one of the volunteers on the Consumer Information Response Team.

Country
Disclaimer
Thank you for using the Consumer Information Response Service ("the Service") to inquire about the meaning of your lab test results.  The Service is provided free of charge by the American Society for Clinical Laboratory Science, which is one of many laboratory organizations that supports Lab Tests Online.
Please note that information provided through this free Service is not intended to be medical advice and should not be relied on as such. Although the laboratory provides the largest single source of objective, scientific data on patient status, it is only one part of a complex biological picture of health or disease. As professional clinical laboratory scientists, our goal is to assist you in understanding the purpose of laboratory tests and the general meaning of your laboratory results. It is important that you communicate with your physician so that together you can integrate the pertinent information, such as age, ethnicity, health history, signs and symptoms, laboratory and other procedures (radiology, endoscopy, etc.), to determine your health status. The information provided through this Service is not intended to substitute for such consultations with your physician nor specific medical advice to your health condition.
By submitting your question to this Service, you agree to waive, release, and hold harmless the American Society for Clinical Laboratory Science and its affiliates or their past or present officers, directors, employees, agents, and Service volunteers (collectively referred to as "ASCLS") and the American Association  for Clinical Chemistry and its affiliates or their past or present officers, directors, employees, agents, and Service volunteers (collectively referred to as "AACC") from any legal claims, rights, or causes of action you may have in connection with the responses provided to the questions that you submit to the Service.
AACC, ASCLS and its Service volunteers disclaim any liability arising out of your use of this Service or for any adverse outcome from your use of the information provided by this Service for any reason, including but not limited to any misunderstanding or misinterpretation of the information provided through this Service.